APA

Ordemann R., Stöhlmacher J., Beuthien-Baumann B., Platzek I., van den Hoff J., Kroschinsky F., Middeke J. M., Platzbecker U., Zietz C., Bornhäuser M. & Ehninger G. (20130314). Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. : Annals of hematology.

Chicago

Ordemann R, Stöhlmacher J, Beuthien-Baumann B, Platzek I, van den Hoff J, Kroschinsky F, Middeke J M, Platzbecker U, Zietz C, Bornhäuser M and Ehninger G. 20130314. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. : Annals of hematology.

Harvard

Ordemann R., Stöhlmacher J., Beuthien-Baumann B., Platzek I., van den Hoff J., Kroschinsky F., Middeke J. M., Platzbecker U., Zietz C., Bornhäuser M. and Ehninger G. (20130314). Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. : Annals of hematology.

MLA

Ordemann R, Stöhlmacher J, Beuthien-Baumann B, Platzek I, van den Hoff J, Kroschinsky F, Middeke J M, Platzbecker U, Zietz C, Bornhäuser M and Ehninger G. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. : Annals of hematology. 20130314.